Fibrogen, Astellas Anemia Deal: $300M, Plus $465M In Milestones
On the heels of a potential $92 million deal with Ilypsa Inc. for Ilypsa's Phase I phosphate binder, Astellas Pharma Inc. has licensed early stage, oral anemia compounds from FibroGen Inc. in a pact worth $300 million up front plus milestones totaling as much as $465 million. (BioWorld Today)